期刊文献+

PHY906研究模式与中药作为癌症辅助治疗剂的现代研究 被引量:3

Chinese traditional herbs as adjuvant therapy for cancer treatment: what we should learn from the case of PHY906.
下载PDF
导出
摘要 Yale大学科学家将传统中药黄芩汤开发成现代植物药制剂PHY906,基于功效主治发现其具有增强化疗药物的治疗效果、降低化疗毒性的作用。学者们围绕这一作用,开展了系统的临床前研究、作用机制研究和临床研究,创立了Phytomics QC质量控制平台。PHY906研究中体现的质量控制理念、询证医学及系统生物学的方法论、良好研究规范值得我们借鉴和学习。中药作为癌症辅助治疗剂潜力巨大,我们需要循序渐进的开展工作,用现代科学和技术证实其有效性和安全性,阐明内在作用机制。 Scientists at Yale University have explored PHY906, which is derived from an ancient Chinese herbal formulation Huang-Qin-Tang, as a standardized botanical drug. Based on traditional claims in Chinese medicine documents, PHY906 was found to enhance the benefits and simultaneously reduce the side effects of the combined chemotherapy agents for cancer. The scientists have undertaken systematic studies, including preclinical studies, mechanisms of action, and clinical studies, for PHY906. A comprehensive platform, Phytomics QC that integrates chemical and biological fingerprints together with a novel biostatistical methodology has been developed to assess the quality of different batches of PHY906. The research approaches of PHYg06 involved quality control, evidence-based medicines, systems biology and "omics" methods. Chinese traditional herbal medicines as adjuvant treatment play important roles during chemotherapy for cancer. We should utilize modem multidisciplinary technologies to elucidate the effectiveness and safety and illustrate the likely mechanistic basis of Chinese traditional herbs.
出处 《海南医学》 CAS 2013年第11期1664-1667,共4页 Hainan Medical Journal
关键词 PHY906 黄芩汤 质量控制 癌症辅助治疗剂 良好研究规范 PHY906 Huang-Qin-Tang Quality control Adjuvant agent for cancer therapy Good practice
  • 相关文献

参考文献17

  • 1Lam W, Bussom S, Guan F, et al. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity [J]. Sci Traasl Med, 2010, 2(45): 45-59. 被引量:1
  • 2Eng C. Are herbal medicines ripe for the cancer clinic? [J]. Sci Traml Med, 2010, 2(45): 45-41. 被引量:1
  • 3Callaway E. How an 1,800-year-old herbal mix heals the gut [J/OL]. Website:http://www.nature.com/news/2010/100818/full/news.2010. 417. html. 被引量:1
  • 4Hedigan K. Cancer: Herbal medicine reduces chemotherapy toxicity [J]. Nat Rev Drug Discov, 2010, 9(10): 765. 被引量:1
  • 5Ye M, Liu SH, Jiang Z, et al. Liquid chromatography/mass spec- trometry analysis of PHY906, a Chinese medicine formulation for cancer therapy [J]. Rapid Commun Mass Spectrom, 2007, 21(22): 3593-3607. 被引量:1
  • 6Zhang W, Saif MW, Dutschman GE, et al. Identification of chemi- cals and their metabolites from PHY906, a Chinese medicine formu- lation, in the plasma of a patient ueated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS) [J]. J ChromatogrA, 2010, 1217(37): 5785-5793. 被引量:1
  • 7Tilton R, Paiva AA, Guan JQ, et al. A comprehensive platform for quality control of botanical drugs (PhytomicsQC): a case study of Huangqin Tang (HQT) and PHY906 [J]. Chin Med, 2010, 5: 30. 被引量:1
  • 8Liu SH, Cheng YC. Old formula, new Rx: the journey of PHY906 as cancer adjuvant therapy [J]. J Ethnopharmacol, 2012, 140(3): 614-623. 被引量:1
  • 9Wang E, Bussom S, Chert J, et al. Interaction of a traditional Chi- nese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor (4): 38. 被引量:1
  • 10Farrell MP, Kummar S. Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer [Y]. Clin Colorectal Cancer, 2003, 2(4): 253-256. 被引量:1

同被引文献55

  • 1李仁廷.半夏泻心汤治疗肿瘤化疗后消化道反应128例[J].陕西中医,2006,27(4):425-425. 被引量:9
  • 2李玉凤.半夏泻心汤治疗化疗相关性腹泻的肠道免疫机制研究.上海中医药大学,2015. 被引量:1
  • 3Chen S,Yueh MF,Bigo C,et al.Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan(CPT-11).Proceedings of the National Academy of Sciences of the United States of America,2013,110:19143-19148. 被引量:1
  • 4Shiozawa T,Tadokoro JI,Fujiki T,et al.Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy:a postmarketing survey.Japanese Journal of Clinical Oncology,2013,43:483-491. 被引量:1
  • 5Kusaba H,Esaki T,Kishimoto J,et al.Phase i study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer.Cancer Chemotherapy and Pharmacology,2013,71:29-34. 被引量:1
  • 6Wagner L,Turpin B,Nagarajan R,et al.Pilot study of vincristine,oral irinotecan,and temozolomide(VOIT regimen)combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.Pediatric Blood Amp Cancer,2013,60:1447-1451. 被引量:1
  • 7闫腾飞,屈原明,宫惠萍,等.中蒙医温病学有效方王氏连朴饮加滑石、黄芩;茵达日-4味汤体外抗轮状病毒的实验研究.//2012全国中医药生物工程技术研究与应用交流研讨会论文集,2012.86-95. 被引量:1
  • 8Cortejoso L,García MI,García-Alfonso P,et al.Differential toxicity biomarkers for irinotecan-and oxaliplatin-containing chemotherapy in colorectal cancer.Cancer Chemotherapy and Pharmacology,2013,71:1463-1472. 被引量:1
  • 9Aguilera D,Mazewski C,Fangusaro J,et al.Response to bevacizumab,irinotecan,and temozolomide in children with relapsed medulloblastoma:a multi-institutional experience.Child's nervous system:Ch NS:official journal of the International Society for Pediatric Neurosurgery,2013,29:589-596. 被引量:1
  • 10赵华.复方黄芩涂膜剂治疗化疗药物所致静脉炎的疗效观察[J].山东医学高等专科学校学报,2008,30(4):263-265. 被引量:1

引证文献3

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部